NIH Grant Success Rates Hit a 30-Year Low — and the Worst May Be Ahead

One in six. That is now the probability that a biomedical researcher's grant application will be funded by the National Institutes of Health — the worst odds since the late 1990s, before the historic budget doubling that built America's modern research enterprise.

The NIH's overall grant success rate dropped to approximately 17% in FY2025, down from 26% the prior year — a staggering nine-percentage-point collapse that has sent shockwaves through every research university, medical school, and independent lab in the country. Early-stage investigators seeking R01-equivalent grants — the foundational currency of academic science — saw their success rates plummet from 29.8% in FY2023 to 18.5%. For 8,740 "at-risk" investigators on the verge of losing all funding, the rate fell to 17%, down from 24% in 2024.

And yet Congress just gave NIH $48.7 billion, a $415 million increase over FY2025. How can funding go up while success rates crater? The answer lies in a policy change that is quietly reshaping the entire landscape of federal biomedical research.

The Multiyear Funding Trap

The primary culprit behind the success rate collapse is the Office of Management and Budget's multiyear funding directive, implemented in FY2025. Under this policy, NIH must commit the full value of a multi-year grant upfront — obligating funds for all years of an award from a single fiscal year's appropriation — rather than distributing costs annually across the life of the grant.

The math is devastating. In FY2024, multiyear-funded grants consumed $1.40 billion, or 16.2% of competing grant funds. By FY2025, that figure more than doubled to $3.61 billion — 30.1% of all competing funds. The R01, the bread-and-butter mechanism that sustains most independent investigators, saw multiyear awards explode from just 21 in FY2024 to 743 in FY2025.

Each dollar committed upfront for a three-year R01 is a dollar unavailable for new awards this year. Analysis published by the Good Science Substack, using a predictive model with 0.83 correlation accuracy, estimates that approximately 75% of NIH's annual appropriations are already committed to previously funded continuations. With multiyear funding devouring an additional share of the remaining 25%, the projected impact for FY2026 is stark: roughly 970 fewer new and competing grants funded compared to a normal baseline — approximately a 10% reduction in available projects.

The NIH awarded 5,564 fewer grants in FY2025 compared to FY2024, and 19 states plus the District of Columbia experienced at least a 10% decline in award numbers.

Why the $48.7 Billion Headline Misleads

Congress deserves credit for rejecting the Trump administration's proposed 40% cut to NIH. The bipartisan FY2026 appropriations package also blocked a proposed 15% cap on indirect cost reimbursement rates — a provision that, had it passed, would have gutted research infrastructure at virtually every university in the country.

But the $415 million increase over FY2025 is functionally consumed by inflation, rising personnel costs, and the structural burden of multiyear commitments. The increase does not translate into more funded grants. It barely keeps the existing portfolio from shrinking further.

The deeper problem is structural. According to modeling analysis, a 4% increase in NIH appropriations — roughly $1.9 billion — would be needed merely to offset the grant losses created by multiyear funding. A 6.7% increase would address both inflation erosion and award reduction simultaneously. Congress delivered a 0.9% increase. The gap between political narrative and mathematical reality has never been wider.

Who Gets Hurt — and Where the Opportunities Remain

The crisis is not evenly distributed. Established investigators with strong track records at well-funded institutions still command significant advantages — their success rates dropped from 27% to 20%, painful but survivable. The sharpest pain falls on early-stage and at-risk investigators, where the difference between 18.5% and the prior year's 29.8% can mean the end of an independent research career.

Several NIH institutes have adjusted paylines downward, meaning that even applications scoring in the top quintile may go unfunded. Investigators who previously might have scored within the fundable range now face the reality that their percentile ranking buys them a position on a waiting list rather than an award.

Yet the landscape is not uniformly bleak. A few strategic realities create openings for well-positioned applicants:

R21 and R03 mechanisms remain relatively accessible. These smaller-scale exploratory and pilot grants have historically carried higher multiyear funding percentages, and their shorter durations mean the upfront commitment burden is lower per award. For investigators developing preliminary data or testing high-risk hypotheses, these mechanisms face less structural pressure.

Institute-specific priorities create pockets of opportunity. Not all 27 NIH institutes are equally affected. Institutes with dedicated congressional set-asides — such as the National Cancer Institute's bypass budget or NIAID's infectious disease portfolio — may maintain higher effective paylines. Investigators who can align their research with an institute's strategic priorities, rather than competing in general pools, improve their odds.

Resubmissions carry disproportionate weight. With fewer new awards available, study sections place increasing emphasis on responsive resubmissions that demonstrate how prior reviewer concerns have been addressed. A strong A1 revision — one that engages criticism directly rather than defensively — stands out in a compressed payline environment.

The $94 Billion Counterargument

Even amid the success rate crisis, the economic case for NIH funding remains overwhelming. According to United for Medical Research's 2026 analysis, NIH's $36.58 billion in FY2025 awards generated $94.15 billion in new economic activity — a return of $2.57 for every dollar invested. Over the past decade, NIH-funded research has supported more than 3.7 million jobs and driven over $822 billion in economic output.

These figures make the multiyear funding policy even more puzzling. By front-loading grant costs and reducing the total number of funded projects, the policy effectively shrinks the economic multiplier. Fewer grants means fewer lab technicians hired, fewer postdocs trained, fewer reagents purchased, fewer startups spun out. The return-on-investment calculation that makes NIH funding one of the most economically productive activities the federal government undertakes depends on volume — the breadth of the research portfolio, not just its depth.

Internal administration documents referenced in the Good Science analysis suggest the policy serves a different purpose: facilitating a potential restructuring toward state-based block granting systems by creating "a relatively clean slate" with fewer ongoing federal commitments. Whether or not that transition materializes, the immediate effect on working scientists is the same.

What Applicants Should Do Now

The 17% success rate is not a temporary dip. With multiyear funding commitments locked in through FY2027 and beyond, the structural pressure on new awards will persist even if Congress delivers modest annual increases. Researchers need to adapt their grant strategies accordingly.

Diversify beyond NIH. NSF, DOE, DOD, and private foundations maintain independent funding streams. The SBIR/STTR programs, freshly reauthorized through 2031, offer a parallel track for translational research that many basic scientists overlook.

Build coalitions. Multi-PI grants and center grants distribute risk and allow investigators to contribute to funded projects even when their individual R01s fall below payline. The shift toward team science is accelerating, and funding agencies reward collaborative proposals that demonstrate complementary expertise.

Target your institute strategically. Each NIH institute publishes its payline, success rate, and program priorities. An application that scores at the 20th percentile might be funded at one institute and unfunded at another. Understanding these differences — and framing your specific aims accordingly — is no longer optional.

Invest in preliminary data. In a 17% success rate environment, reviewers are looking for reasons to say yes. Robust preliminary data that de-risks the proposed experiments is the single strongest differentiator between funded and unfunded applications at equivalent innovation levels.

The paradox of American biomedical research in 2026 is that the money is there — $48.7 billion, the highest appropriation in NIH history — but the structural machinery for distributing it has been redesigned in ways that lock out hundreds of qualified investigators. For researchers navigating this landscape, tools like Granted can help identify alternative funding sources and build competitive applications before the window on FY2026 submissions closes.